Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage
New York, January 7, 2026, 11:41 EST — Regular session. Eli Lilly and Company shares were up 3.3% at $1,099.44 in late morning trade, pushing back toward the $1,100 level as investors cheered fresh deal chatter around the drugmaker’s pipeline. (https://www.reuters.com/markets/companies/LLY.N/) The lift matters now because the market is watching how Lilly defends its growth run while competitors push pill versions of obesity drugs and pricing stays in flux. Investors have rewarded companies that can keep adding late-stage shots on goal without derailing margins. The Wall Street Journal reported Lilly is in advanced talks to buy Ventyx Biosciences for more